Palbociclib in Combination With Hormone Therapy for Luminal Her2-Negative Metastatic Breast Cancer: New Highly Effective Strategy of Drug Treatment

Tumors of female reproductive system
doi 10.17650/1994-4098-2017-13-3-28-40
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Publishing House ABV Press

Related search

Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer

Frontiers in Oncology
Cancer ResearchOncology
2018English

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

Geburtshilfe und Frauenheilkunde
GynecologyMidwiferyMaternityObstetrics
2019English

Capecitabine in Combination With Docetaxel in First Line in HER2-Negative Metastatic Breast Cancer: An Observational Study

Pathology and Oncology Research
MedicineForensic MedicinePathologyOncologyCancer Research
2016English

Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer: Impact of CDK4/6 Inhibitors on the Current Treatment Paradigm

Asia-Pacific Journal of Clinical Oncology
MedicineOncology
2018English

Phase II Trial of Fulvestrant With Metronomic Capecitabine for Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Clinical Breast Cancer
Cancer ResearchOncology
2014English

HER2-Orientated Therapy in Early and Metastatic Breast Cancer

Breast Care
SurgeryOncology
2016English

Retrospective Analysis of HER2 Therapy Interruption in Patients Responding to the Treatment in Metastatic HER2+ Breast Cancer

ESMO Open
Cancer ResearchOncology
2017English

CDK4/6 Inhibitors for Hormone Receptor-Positive HER2-negative Metastatic Breast Cancer: Does One Size Fit All?

Future Medicinal Chemistry
Drug DiscoveryMolecular MedicinePharmacology
2019English

Efficacy and Safety of Palbociclib Plus Endocrine Therapy in North American Women With Hormone Receptor‐positive/Human Epidermal Growth Factor Receptor 2‐negative Metastatic Breast Cancer

Breast Journal
Internal MedicineSurgeryOncology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy